Targeting PTEN loss holds promise as a therapeutic strategy: a recent study by Zhang et al. using an in situ lung cancer model demonstrated that precise delivery of PTEN mRNA restored PTEN function, alleviated immunosuppression, and improved the local immune environment in the lungs [52]. The gene discussed is PTEN; the disease is lung carcinoma.